康恩贝(600572.SH)：子公司盐酸丙卡特罗吸入溶液获得药品注册证书

Core Viewpoint - Kang En Bei (600572.SH) has received approval from the National Medical Products Administration for two specifications of the inhalation solution of salbutamol, which is primarily used to alleviate symptoms of bronchial asthma, chronic bronchitis, and emphysema, among other airflow-restricted diseases [1] Group 1 - The company’s wholly-owned subsidiary, Zhejiang Jinhua Kang En Bei Biopharmaceutical Co., Ltd., is responsible for the newly approved medication [1] - The inhalation solution is aimed at treating respiratory conditions that involve airflow limitation [1]